Address
Friedrich-Miescher-Strasse 15
Tübingen, 72076
Germany
Phone
49 7071 9883 0
Website
Sector
Healthcare
Industry
Biotechnology
Employees
825
First IPO Date
August 14, 2020
| Name | Title | Pay | Year Born |
| Alexander Zehnder | Chief Executive Officer, MD & Member of Management Board | 1.09M | 1970 |
| Ulrike Gnad-Vogt | Senior Vice President & Area Head of Oncology | 333,978 | 1973 |
| Axel-Sven Malkomes | Chief Financial Officer & Member of Executive Board | 572,012 | 1967 |
| Malte Greune | Chief Operating Officer, Member of Management Board & MD | 635,588 | 1965 |
| Thaminda Ramanayake | Chief Business Officer & Member of Executive Board | 689,513 | 1977 |
| Myriam Mendila | Chief Scientific Officer, Head of R&D, MD & Member of the Management Board | 711,669 | 1966 |
| Patrick Baumhof | Senior Vice President of Technology | 0 | N/A |
| Sarah Fakih | Vice President of Corporate Communications & Investor Relations | 0 | N/A |
| Marco Rau | General Counsel | 0 | N/A |
| Slavica Stevanovic-Heck | Head of Human Resources | 0 | N/A |
CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase 1 clinical investigation. Another key candidate, CV7202, an mRNA prophylactic targeting the rabies virus glycoprotein, has successfully completed its Phase 1 clinical evaluation. Additionally, CVSQIV, aimed at influenza, is also undergoing Phase 1 clinical trials. Further vaccine development efforts are directed towards lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and a universal influenza solution. Beyond its vaccine initiatives, CureVac is also engaged in developing RNA-based immunotherapies for cancer. For instance, CV8102, an immunotherapy, is currently undergoing Phase 1 trials for the treatment of cutaneous melanoma, adenoidcystic carcinoma, and squamous cell carcinoma affecting the skin, head, and neck. The company was established in 2000 and operates from its main office in Tübingen, Germany.